Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studiesCollaboration underscores Lonza's commitment to…
NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Arsenal Capital Partners ("Arsenal"), a leading private equity firm specializing in building technology-rich,…
The cloud-based platform enhances FibroScan® capabilities, providing advanced tools for data-driven liver disease management PARIS, Nov. 4, 2024 /PRNewswire/ -- Liver…
SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company…
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael WellerAccess the segment here HOUSTON, TX / ACCESSWIRE /…
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of…
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE…
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…
ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical…
VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…